Please assess the completion status of the following clinical trial:

Trial Title: Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have CML in any phase (CP, AP, or BP of any phenotype) or Ph+ ALL~* Previously treated with and developed resistance or intolerance to dasatinib or nilotinib OR developed the T3151 mutation after any tyrosine kinase inhibitor (TKI) therapy~* ≥18 years old~* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2~* Minimum life expectancy of ≥3 months~* Adequate kidney function~* Adequate liver function~* Normal pancreatic function~* Normal QT Fridericia-corrected interval (QTcF) ≤450 ms for males and ≤470 ms for females~* Negative pregnancy test (if woman of childbearing potential)~* Agree to use effective form of contraception (as applicable)~* Ability to comply with study procedures, in the Investigator's opinion~Exclusion Criteria:~* Received prior TKI treatment within 7 days prior to receiving the first dose of ponatinib, or have not recovered from adverse events (except alopecia) due to agents previously administered.~* Received other therapies as follows:~  1. For CML chronic phase (CP) and accelerated phase (AP) participants, received hydroxyurea or anagrelide within 24 hours prior to receiving the first dose of ponatinib; interferon, cytarabine, or immunotherapy within 14 days prior to first dose of ponatinib; or any other cytotoxic chemotherapy, radiotherapy, or investigational therapy within 28 days prior to receiving the first dose of ponatinib.~ 2. For CML blast phase (BP) participants, received chemotherapy within 14 days prior to the first dose of ponatinib.~ 3. For Ph+ ALL participants, received corticosteroids within 24 hours before the first dose of ponatinib; or vincristine within 7 days prior to the first dose of ponatinib; or received other chemotherapy within 14 days prior to the first dose of ponatinib.~* Underwent stem cell transplant \<60 days prior to receiving first dose of ponatinib~* Evidence of on-going graft versus-host disease (GVHD), or GVHD requiring immunosuppressive therapy~* Taking medications that are known to be associated with Torsades de Pointes~* Require concurrent treatment with immunosuppressive agents (other than corticosteroids prescribed for a short course of therapy)~* Previously treated with ponatinib~* CML CP participants are excluded if they are in Complete cytogenetic response (CCyR)~* Participants with CML AP, CML BP, or Ph+ ALL are excluded if they are in Major Hematologic Response (MaHR).~* Have active Central Nervous System (CNS) disease~* Have significant or active cardiovascular disease~* Have a significant bleeding disorder unrelated to CML or Ph+ALL~* Have a history of pancreatitis or alcohol abuse~* Have uncontrolled hypertriglyceridemia (triglycerides \>450 mg/dL)~* Have malabsorption syndrome or other gastrointestinal illness that could affect absorption of ponatinib~* Diagnosed with another primary malignancy in the past 3 years~* Pregnant or lactating~* Underwent major surgery within 14 days prior to first dose of ponatinib~* Have ongoing or active infection~* Suffer from any other condition or illness that would compromise safety or interfere with evaluation of the drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A: CP-CML R-I (Type: EXPERIMENTAL): CP-CML participants R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- Cohort B: CP-CML with T315I Mutation (Type: EXPERIMENTAL): CP-CML participants who had T315I mutation of breakpoint cluster region-Abelson complex (BCR-ABL) were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- Cohort C: Accelerated Phase (AP)-CML R-I (Type: EXPERIMENTAL): AP-CML R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- Cohort D: AP-CML with T315I Mutation (Type: EXPERIMENTAL): AP-CML participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- Cohort E: Blast Phase (BP)-CML/Ph+ ALL R-I (Type: EXPERIMENTAL): BP-CML or Ph+ ALL R-I to dasatinib or nilotinib or Ph+ ALL R-I to dasatinib or nilotinib were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- Cohort F: BP-CML or Ph+ ALL with T315I Mutation (Type: EXPERIMENTAL): BP-CML or Ph+ ALL participants who had T315I mutation of BCR-ABL were administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).
- Unassigned to Cohorts A-F (Type: EXPERIMENTAL): Participants who were not assigned to any of the cohorts and have no T315I mutation at study entry and were not R-I to dasatinib or nilotinib, administered ponatinib 45 mg, tablet, orally, once daily until disease progression or development of intolerance or if they met one or more of the protocol defined criteria for discontinuation (Up to approximately 48 months).

Based on this trial design, predict the completion outcome and termination type (if applicable).